DK2593797T3 - Hidtil ukendte fremgangsmåder til proteinevolution - Google Patents

Hidtil ukendte fremgangsmåder til proteinevolution Download PDF

Info

Publication number
DK2593797T3
DK2593797T3 DK11807192.7T DK11807192T DK2593797T3 DK 2593797 T3 DK2593797 T3 DK 2593797T3 DK 11807192 T DK11807192 T DK 11807192T DK 2593797 T3 DK2593797 T3 DK 2593797T3
Authority
DK
Denmark
Prior art keywords
protein evolution
unknown
procedures
unknown procedures
evolution
Prior art date
Application number
DK11807192.7T
Other languages
English (en)
Inventor
Jay M Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Application granted granted Critical
Publication of DK2593797T3 publication Critical patent/DK2593797T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1058Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50Mutagenesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
DK11807192.7T 2010-07-16 2011-03-04 Hidtil ukendte fremgangsmåder til proteinevolution DK2593797T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36521610P 2010-07-16 2010-07-16
PCT/US2011/027252 WO2012009026A2 (en) 2010-07-16 2011-03-04 Novel methods of protein evolution

Publications (1)

Publication Number Publication Date
DK2593797T3 true DK2593797T3 (da) 2019-08-05

Family

ID=45469988

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18194688.0T DK3435087T3 (da) 2010-07-16 2011-03-04 Hidtil ukendte fremgangsmåder til proteinevolution
DK11807192.7T DK2593797T3 (da) 2010-07-16 2011-03-04 Hidtil ukendte fremgangsmåder til proteinevolution

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18194688.0T DK3435087T3 (da) 2010-07-16 2011-03-04 Hidtil ukendte fremgangsmåder til proteinevolution

Country Status (9)

Country Link
US (3) US10106576B2 (da)
EP (2) EP3435087B1 (da)
CN (2) CN105924499B (da)
AU (1) AU2011279747B2 (da)
CA (1) CA2804746C (da)
DK (2) DK3435087T3 (da)
ES (2) ES2966088T3 (da)
SG (2) SG187033A1 (da)
WO (1) WO2012009026A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170168A1 (en) 2012-05-10 2013-11-14 Bioatla Llc Multi-specific monoclonal antibodies
EP3092491B1 (en) 2014-01-07 2018-10-31 Bioatla, LLC Proteins targeting orthologs
CN109696550B (zh) * 2017-10-20 2022-08-26 成都蓝瑙生物技术有限公司 用于脑中风的发光elisa体液样品稳定化用水溶液
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
WO2023044333A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
WO2023044343A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023196931A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
WO1989006700A1 (en) 1988-01-21 1989-07-27 Genentech, Inc. Amplification and detection of nucleic acid sequences
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP1361273A3 (en) 1992-11-24 2004-02-11 G.D. Searle & Co. Interleukin-3 (IL-3) multiple mutation polypeptides
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
CA2239686A1 (en) * 1995-12-07 1997-06-12 Recombinant Biocatalysis, Inc. Method of screening for enzyme activity
US20030219752A1 (en) 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
PL362324A1 (en) 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
JP2004532038A (ja) * 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
WO2007047578A2 (en) 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
US20090309617A1 (en) 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US7947495B2 (en) 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
DK3156485T3 (da) * 2009-07-17 2019-01-07 Bioatla Llc Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelser og eksprimering i produktionsværter
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
EP2593797A4 (en) 2014-01-08
EP2593797A2 (en) 2013-05-22
ES2966088T3 (es) 2024-04-18
US10106576B2 (en) 2018-10-23
WO2012009026A2 (en) 2012-01-19
US20210017221A1 (en) 2021-01-21
CN103003696A (zh) 2013-03-27
EP3435087A1 (en) 2019-01-30
CA2804746C (en) 2022-01-11
AU2011279747B2 (en) 2015-07-16
US10829513B2 (en) 2020-11-10
EP2593797B1 (en) 2019-05-08
EP3435087B1 (en) 2023-11-08
CN105924499B (zh) 2020-09-15
SG187033A1 (en) 2013-02-28
US20180362576A1 (en) 2018-12-20
US20130116125A1 (en) 2013-05-09
CN103003696B (zh) 2016-06-01
CA2804746A1 (en) 2012-01-19
CN105924499A (zh) 2016-09-07
WO2012009026A3 (en) 2012-09-07
ES2741175T3 (es) 2020-02-10
US11639365B2 (en) 2023-05-02
DK3435087T3 (da) 2023-11-27
SG10201902596TA (en) 2019-04-29
AU2011279747A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
LTC2521568I2 (lt) Plazmos kalikreiną surišantys baltymai
DK2593797T3 (da) Hidtil ukendte fremgangsmåder til proteinevolution
CO6950481A2 (es) Inhibidores de proteínas quinasas
DK3053932T3 (da) Hidtil ukendte ctla4-ig-immunoadhesiner
DK2606061T3 (da) Bindingsproteiner til hepcidin
DK2536830T3 (da) Polypeptider
DK2443154T3 (da) Bispecifikke antigenbindingsproteiner
DK2625295T3 (da) High-throughput-immunsekvensering
CR20120576A (es) Inhibidores de pirazolil quinazolina cinasa
DK2591099T3 (da) Kimære koagulationsfaktorer
DK2646647T3 (da) Frakturkarakterisering
DK2501822T3 (da) Fremgangsmåder til forbedret proteinproduktion
BR112012015988A2 (pt) método
BR112013011934A2 (pt) configuração subframe
BR112013014989A2 (pt) completamento de poço
DK3275896T3 (da) Fremgangsmåde til at opnå antistoffer
BR112014004902A2 (pt) peptídeos
BR112013012217A2 (pt) incubadora
DK2598514T3 (da) Proteinoprensning
CO6791565A2 (es) Anticuerpos anti-notch1
BR112013008347A2 (pt) polipeptídeos de variantes cbh i
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
DK2564396T3 (da) Fremgangsmåde til isotop-fremstilling
DK2598516T3 (da) Fremgangsmåde til proteinoprensning
BR112012023891A2 (pt) método